Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen to Distribute JCSG's Protein Crystallization Screens; Shareholders OK Digene Buy

NEW YORK (GenomeWeb News) — Qiagen said today it will distribute protein crystallization screens developed by the Joint Center for Structural Genomics.

Separately today the company said that its shareholders have approved its $1.6 billion acquisition of Digene.

Terms of Qiagen’s agreement with JCSG call for the company to distribute the new screens, known as the JCSG Core Suites I-IV. The company said these screens resulted from JCSG’s analysis of more than 500,000 high-throughput crystallization experiments.

"These new screens are the result of mining the vast database of crystallization experiments performed by the JCSG,” said Qiagen’s global business director of proteins Kai te Kaat.

JCSG is one of the Protein Structure Initiative’s Genomics Production Centers, and is funded by the National Institute for General Medical Sciences.

JCSG principal investigator Ian Wilson said the supplier agreement with Qiagen “enables the fruits of the NIH Protein Structure Initiative to become available to all structural biologists and allow them the opportunity to enhance their own individual success rates in protein crystallization."

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.